Chronic myeloid leukemia diagnosed in pregnancy: management and outcome of 87 patients reported to the European LeukemiaNet international registry

• Published in: Leukemia 2024-04, Vol.38 (4), p.788-795
• Main Authors: Chelysheva, Ekaterina, Apperley, Jane, Turkina, Anna, Yassin, Mohamed A., Rea, Delphine, Nicolini, Franck E., Barraco, Daniela, Kazakbaeva, Khamida, Saliev, Sukhrob, Abulafia, Adi Shacham, Al-Kindi, Salam, Byrne, Jennifer, Robertson, Harry F., Cerrano, Marco, Shmakov, Roman, Polushkina, Evgenia, de Fabritiis, Paolo, Trawinska, Malgorzata Monika, Abruzzese, Elisabetta
• Format: Article
• Language: English
• Subjects: 692/699; 692/699/1541/1990/2331; Abnormalities; Birth rate; Birth weight; Cancer Research; Childbirth & labor; Chronic myeloid leukemia; Critical Care Medicine; Disease control; Female; Hematology; Humans; Hydroxyurea; Imatinib; Imatinib Mesylate; Intensive; Interferon; Interferon-alpha - therapeutic use; Internal Medicine; Kinases; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - diagnosis; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy; Leukemia, Myeloid, Chronic-Phase; Low birth weight; Medicine; Medicine & Public Health; Myeloid leukemia; Oncology; Placenta; Pregnancy; Protein Kinase Inhibitors - adverse effects; Treatment Outcome; Tyrosine; α-Interferon
• ISSN: 0887-6924; 1476-5551; 1476-5551
• DOI: 10.1038/s41375-024-02183-0

The management of chronic myeloid leukemia (CML) diagnosed during pregnancy is a rare and challenging situation. We report the treatment and outcome of 87 cases diagnosed in chronic phase from 2001–2022 derived from the largest international observational registry, supported by the European LeukemiaNet (ELN), of 400 pregnancies in 299 CML women. Normal childbirth occurred in 76% without an increased rate of birth abnormalities or life-threatening events, including in patients untreated or treated with interferon-α and/or imatinib in 2nd–3rd trimester. The low birth weight rate of 12% was comparable to that seen in the normal population. Elective and spontaneous abortions occurred in 21% and 3%, respectively. The complete hematologic response rate before labor was 95% with imatinib and 47% with interferon only. No disease progression during pregnancy was observed, 28% of the patients switched their therapy at varying times after delivery. Treatment options balance the efficacy and safety for mother and infant: interferon-α can commence in the 1st trimester and continued throughout in cases of good disease control and tolerability. Because of limited placental crossing, selected tyrosine kinase inhibitors (imatinib and nilotinib) seem to be safe and effective options in 2nd and 3rd trimester while hydroxycarbamide offers few benefits.